Toshitaka Nagao

Tokyo Medical University

Papers

1

Total Citations

11

H-Index

1

About

Dr. Toshitaka Nagao is a leading urological pathologist whose research focuses on refining prostate cancer prognostication through detailed histopathological analysis. His major contributions center on the clinical significance of cribriform morphology—a specific growth pattern within Gleason pattern 4 tumors—and its correlation with biochemical recurrence (BCR) after radical prostatectomy. In his landmark 2024 study, Dr. Nagao demonstrated that the ratio of cribriform morphology area is a critical predictor of BCR in patients with Gleason score 4+4 prostate cancer following robot-assisted radical prostatectomy. This work, which has already garnered 11 citations, provides surgeons and oncologists with a more precise tool for risk stratification, moving beyond traditional Gleason grading alone. By isolating the impact of cribriform pattern size and percentage in a previously understudied homogeneous cohort, Dr. Nagao has advanced personalized treatment planning, helping to identify patients who may benefit from adjuvant therapies versus those who can safely undergo active surveillance. His research bridges pathology and clinical urology, offering actionable insights that improve patient outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Significance of the cribriform morphology area ratio for biochemical recurrence in Gleason score 4 + 4 prostate cancer patients following robot‐assisted radical prostatectomy
11 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Tokyo Medical University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago